Sanofi Announces Call for Submissions for Ignite: The Diabetes Ideas Challenge
PARIS, April 16, 2013
PARIS, April 16, 2013 /PRNewswire/ --
− Worldwide invitation to create and submit concepts
for a potential next-generation insulin delivery device −
Sanofi (EURONEXT: SANand NYSE: SNY) announced today that it is accepting
submissions for Ignite: The Diabetes Ideas Challenge ("Ignite Challenge") .
The web-based Ignite Challenge invites patients, caregivers, designers,
engineers, and innovators from around the globe to submit ideas that could
shape the features and design of a next-generation, insulin delivery device
for people with diabetes. Building on the user experience and technology
advances of the past 30 years, the Ignite Challenge seeks to address the
critical need for innovative, easy-to-use and cost-effective devices for
delivering injectable medications for the treatment of diabetes.
" Over time and across geographies, w e observe a consistent increase in the
use of injectable medications among the more than 3 70 million people
living with diabete s , " said Pierre Chancel, Senior Vice President, Global
Diabetes, Sanofi. " Through innovation challenges such as the Ignite
Challenge, Sanofi hopes to foster creative thinking and new ideas that may
improve the way people manage their diabetes in the future using
patient-friendly and innovative devices . "
Many people living with diabetes use insulin and an insulin delivery device as
part of their overall treatment plan, which may include other medications,
along with a healthy diet and exercise. The Ignite Challenge turns to
innovators to submit ideas that may advance the technology and design of
today's insulin delivery devices, while maintaining key factors including
reliability, ease of use and aesthetic appeal. The Ignite Challenge will award
ten winning submissions $5,000 each for their original ideas.
Challenge concept submissions must meet the following three criteria:
*Accessibility - concept must be usable by a broad population, including
the young and old, or people with impaired hand use or vision.
*Appropriateness - concept must be easy to integrate into daily life and be
of high quality. Device should be portable and aesthetically pleasing. It
has to be recognizable as an injection device, while not appearing overtly
*Functionality - Device must meet functional requirements as a medical
tool, should enable accurate delivery, have functionality for extended
periods without electricity, and the ability to store more than one dose
of insulin per disposable device.
" Sanofi understands the importance of going beyond the molecule to help
people manage the complex challenges of diabetes, " said Christoph Heinemann,
Vice President Strategy and Portfolio Management, Global Diabetes, Sanofi. "
While we are committed to our current and award-winning insulin
delivery device offerings, we understand the importance of exploring new,
innovative approaches that may take years to develop and test but that
could provide additional offerings to people living with diabetes. "
Over the past few years, innovation challenges have become an integral part of
Sanofi's commitment to diabetes care. This year marks the company's third
annual Data Design Diabetes™ Innovation Challenge in the U.S., which has a
three-part aim: innovation in the quality, delivery, and cost of diabetes
care. Sanofi U.S. also developed the Partners in Patient Health Collaborate -
Activate Innovation Challenge in 2012, which awarded teams that delivered
novel approaches to better engage patients in healthcare. The Ignite Challenge
continues this momentum by encouraging the development of solutions that show
potential to directly meet patients' needs.
The full timeline for the Ignite Challenge is as follows:
Open Submissions: April 8 - May 10
The Ignite Challenge website is open for submissions and will remain open
until May 10, 2013.
Submission Review and Judging: May 13 - May 24
An expert panel of judges will review the Ignite Challenge submissions.
Winner Announcements: May 30
Ten winners will be announced and each awarded $5,000.
About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes by
delivering innovative, integrated and personalized solutions. Driven by
valuable insights that come from listening to and engaging with people living
with diabetes, the Company is forming partnerships to offer diagnostics,
therapies, services and devices, including intelligent blood glucose
monitoring systems. Sanofi markets both injectable and oral medications for
people with type 1 or type 2 diabetes.
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs.Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
This press release contains forward-looking statements. Forward-looking
statements are statements that are not his to rical facts.These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance.Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, inves to rs are cautioned that
forward-looking information and statements are subject to various risks
and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and developments
to differ materially from those expressed in, or implied or projected by,
the forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regula to ry authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application
that may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes there to , the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under "Risk Fac to rs" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2012. Other than as
required by applicable law, Sanofi does not undertake any obligation to
update or revise any forward-looking information or statements.
Contact: Contacts: Media Relations : Marisol Peron, Tel.: +(33)1-53-77-46-46,
email@example.com ; Global Diabetes Division Communications, Tilmann
Kiessling, Tel.: + (49)1-72-61-59-29-1, firstname.lastname@example.org
Press spacebar to pause and continue. Press esc to stop.